Why the study?
The associations between both the progression and regression of liver fibrosis and subclinical atherosclerosis in patients with MASLD needed investigation.
Does the progression or persistence of liver fibrosis increase the risk of subclinical atherosclerosis in patients with MASLD?
Does the progression or persistence of liver fibrosis increase the risk of subclinical atherosclerosis in patients with MASLD?
Answers are grounded in this paper and cite their sources.
Cross-sectional and longitudinal study examines liver fibrosis impact on subclinical atherosclerosis risk in MASLD patients, suggesting a need for monitoring.
BACKGROUND: This study investigated the associations between both the progression and regression of liver fibrosis and subclinical atherosclerosis in patients withmetabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: We conducted a cross-sectional analysis of 5,633MASLD participants who underwent transient elastography and carotid ultrasonography (Stage I). Additionally, a longitudinal study followed 2,670MASLD individuals without carotid atherosclerosis (CAS) at baseline, who underwent at least two health check-up examinations (Stage II). We used CAS and brachial ankle pulse wave velocity (baPWV) as markers of subclinical atherosclerosis and calculated the noninvasive fibrosis index FIB-4 to evaluate the probability of fibrosis. RESULTS: In Stage I study, liver fibrosis was associated with increased CAS risk (OR = 1.17, 95%CI1.01-1.37, P = 0.045) and elevated baPWV (OR = 1.49, 95%CI 1.06-2.09, P = 0.022). In Stage II study, during a median of 24 months of follow-up, 466 (17.45%)MASLD patients developed CAS. Compared to patients with stable low probability, those who progressed to a high-intermediate probability of advanced fibrosis had a higher risk of incident CAS (HR = 1.89, 95%CI1.42-2.51, P < 0.001). In addition, persistent high-intermediate probability and regression to low probability of advanced fibrosis were associated with 2.32-fold (95%CI 1.86-2.89, P < 0.001) and 1.82-fold (95% 1.22-2.71, P = 0.004) increased risk of incident CAS, respectively. Moreover, persistent high-intermediate probability was independently correlated with elevated baPWV risk (HR = 3.17, 95%CI 1.76-5.71, P < 0.001). CONCLUSIONS: Persistent or progression to high-intermediate probability of fibrosis was associated with an increased risk of subclinical atherosclerosis, while regression to low probability of fibrosis does not significantly reduce this risk.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: